New drug delivery option for reusable devices

By Kirsty Barnes

- Last updated on GMT

Related tags Pharmaceutical drug Ampac

Ampac have developed a novel, lightweight, high-barrier pouch,
offering pharmaceutical manufacturers a new option for delivering
pulmonary drugs in a more efficient manner than traditional
container types.

It is designed to work in conjunction with devices which currently rely on either glass vials or aerosol containers for pulmonary drug delivery.

Flexi 6833, is a polyester/foil/sealant layer lamination that can be converted into a drug delivery pouch for liquid or powder-based products.

The thin structure allows the flexible pouch to fully collapse which facilitates evacuation while preventing air from entering, offering several dispensing and manufacturing advantages.

The fully-filled container positively contributes to drug shelf life by eliminating the need for head space gasses currently used with glass vials.

The fully collapsible structure eliminates the need for the pressurization step required with aerosol containers, thus reducing production expenses.

Ampac,​ traditionally a retail-bag manufacturer, has recently made a concerted effort to diversify its business into areas such as medical and pharmaceuticals packaging, through a combination of acquisitions and internal growth.

Retail bags still represent about 60 percent of the company's sales, but that percentage is shrinking as its medical and pharmaceuticals packaging, food and consumer business grows faster.

The medical and pharmaceuticals markets are fueling double-digit packaging growth as hospitals and drug-makers are breaking up multi-dose drug packs into single-dose plastic and foil packages that can be tracked more easily with a bar code.

Ampac is and international packaging company with nine operating sites in North America and Asia employing approximately 850 people with revenues in excess of $200 million (€166 million) annually.

Related topics Drug Delivery Delivery technologies

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers